Over the past two years, I have fielded an increasing number of questions about peptides from readers, patients and ...

Have you ever thought why we tend to struggle more with lifestyle diseases like diabetes and hypertension in summer as ...

Health Canada ‌​approved on Tuesday the first generic ​version of ​Danish drugmaker Novo ‌Nordisk's Ozempic drug.

Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company's recent U.S. business reset reflected a ...

Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched ...

3 small-cap biotechs with potential breakthroughs in 2024 Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal ...

MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key ...

Researchers from the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have reached a significant advance in ...

Scientists found a key to Ozempic’s rise in Gila monster venom, leading to Byetta and the modern era of GLP-1 diabetes and ...

Injectable peptides are being touted by podcasters, influencers, celebrities and US Health Secretary Robert F. Kennedy Jr. as ...

My generation—which is to say, the pillbox generation—came of age during the 1990s. The number of adults who were taking five ...

Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ...